Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma

SIMPLE SUMMARY: Immunotherapy-based treatment options have become standard of care in metastatic renal cell carcinoma. Despite significant improvement in overall survival with these therapies, the tumors of many patients will eventually progress. This review highlights the ongoing efforts to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucker, Matthew D., Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565517/
https://www.ncbi.nlm.nih.gov/pubmed/32961934
http://dx.doi.org/10.3390/cancers12092662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565517/
https://www.ncbi.nlm.nih.gov/pubmed/32961934
http://dx.doi.org/10.3390/cancers12092662

Ejemplares similares